SCHEMBL5498294

SCHEMBL5498294

CCCCCCCCCCCCC/C=C/C(O)=C/C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.56
PPARG P37231 5/20 0.54
PPARA Q07869 5/20 0.54
TERT O14746 3/20 0.53
PPARD Q03181 3/20 0.53
TOP1 P11387 3/20 0.53
MAPT P10636 2/20 0.53
BLM P54132 2/20 0.53
HSD17B10 Q99714 2/20 0.53
FABP4 P15090 2/20 0.53
GMNN O75496 1/20 0.53
USP2 O75604 1/20 0.53
LMNA P02545 1/20 0.53
CYP1A2 P05177 1/20 0.53
POLB P06746 1/20 0.53
CYP2C9 P11712 1/20 0.53
ALOX15 P16050 1/20 0.53
APEX1 P27695 1/20 0.53
CYP2C19 P33261 1/20 0.53
RECQL P46063 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4751614 1.00 PTPN1 (0.56) PTPN1PPARGPPARATERTPPARD
SCHEMBL5498298 1.00 PTPN1 (0.56) PTPN1PPARGPPARATERTPPARD
SCHEMBL3345156 1.00 PTPN1 (0.56) PTPN1PPARGPPARATERTPPARD
SCHEMBL8083753 1.00 PTPN1 (0.56) PTPN1PPARGPPARATERTPPARD
SCHEMBL4751612 1.00 PTPN1 (0.56) PTPN1PPARGPPARATERTPPARD
SCHEMBL8083757 1.00 PTPN1 (0.56) PTPN1PPARGPPARATERTPPARD
SCHEMBL3345152 1.00 PTPN1 (0.56) PTPN1PPARGPPARATERTPPARD
SCHEMBL15515132 0.98 PTPN1 (0.53) PTPN1PPARGPPARATERTPPARD
SCHEMBL15515133 0.98 PTPN1 (0.53) PTPN1PPARGPPARATERTPPARD
SCHEMBL8075370 0.87 FASN (0.59) PTPN1PPARGPPARATERTPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014039940-A1 CELLS AND METHODS FOR THE PRODUCTION OF RHAMNOLIPIDS LOGOS TECHNOLOGIES LLC (US) 2014-03-13 WO claimed
US-9523673-B2 Methods for diagnosing and identifying modulators of membrane potentials in bipolar disorder and attention deficit hyperactivity disorder PSYCHNOSTICS, LLC (US) 2016-12-20 US disclosed
US-9029342-B2 Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-05-12 US disclosed
US-20140248652-A1 METHODS FOR DIAGNOSING AND IDENTIFYING MODULATORS OF MEMBRANE POTENTIALS IN BIPOLAR DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER PSYCHNOSTICS, LLC (US) 2014-09-04 US disclosed
US-20140128588-A1 COMPOSITIONS OF MATTER THAT REDUCE PAIN, SHOCK, AND INFLAMMATION BY BLOCKING LINOLEIC ACID METABOLITES AND USES THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-05-08 US disclosed
WO-2014039940-A1 CELLS AND METHODS FOR THE PRODUCTION OF RHAMNOLIPIDS LOGOS TECHNOLOGIES LLC (US) 2014-03-13 WO disclosed
US-20120195862-A1 BIOMECHANICAL INDUCTION OF HEMATOPOIESIS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2012-08-02 US disclosed
US-20110065801-A1 ENZYMATIC SYNTHESIS OF SPHINGOLIPIDS EVONIK GOLDSCHMIDT GMBH (DE) 2011-03-17 US disclosed
US-20070066572-A1 Neuroprotection by positively-charged nitroxides NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-03-22 US disclosed
US-20060165630-A1 Use of amide or ester of sugar and of fatty acid, for treating and/or preventing dry skin L'OREAL (FR) 2006-07-27 US disclosed
US-20060111407-A1 Association between a heterocyclic compound stimulating lipid and carbohydrate metabolisms and an antioxidant agent for treating obesity CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2006-05-25 US disclosed
US-20060079488-A1 Methods of treating and preventing bone loss ALLARD JOHN D 2006-04-13 US disclosed
US-20060014820-A1 Lipid-amino acid conjugates and methods of use NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-01-19 US disclosed
US-20060002911-A1 Association between a ppar ligand and an antioxidant agent and use thereof for treating obesity LES LABORATORIES SERVIER (FR) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014820-A1 Lipid-amino acid conjugates and methods of use SLC27A2, SLC27A1, FABP2 PTPN1 2487/4885PPARG 160/4885PPARA 224/4885
US-20060079488-A1 Methods of treating and preventing bone loss ALOX5, SOST, ALOX15B PTPN1 3739/4885PPARG 616/4885PPARA 410/4885
US-20070066572-A1 Neuroprotection by positively-charged nitroxides NLN, HSPE1, AIFM1 PTPN1 3268/4885PPARG 1182/4885PPARA 1155/4885
US-20140128588-A1 COMPOSITIONS OF MATTER THAT REDUCE PAIN, SHOCK, AND INFLAMMATION BY BLOCKING LINOLEIC ACID METABOLITES AND USES THEREOF FABP1, HSPBP1, LTA PTPN1 4765/4885PPARG 312/4885PPARA 39/4885
US-20110065801-A1 ENZYMATIC SYNTHESIS OF SPHINGOLIPIDS ASAH1, SMPD1, ASAH2 PTPN1 3345/4885PPARG 2483/4885PPARA 2717/4885
US-20060111407-A1 Association between a heterocyclic compound stimulating lipid and carbohydrate metabolisms and an antioxidant agent for treating obesity PC, GPR119, LIPC PTPN1 3202/4885PPARG 19/4885PPARA 44/4885
US-20060165630-A1 Use of amide or ester of sugar and of fatty acid, for treating and/or preventing dry skin CUTA, SCD5, SCD PTPN1 2278/4885PPARG 121/4885PPARA 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.